DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 197 filers reported holding DENALI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $475 | +28.0% | 16,097 | 0.0% | 0.02% | +16.7% |
| Q1 2023 | $371 | -54.6% | 16,097 | -45.3% | 0.02% | -60.0% |
| Q4 2022 | $818 | -99.7% | 29,426 | +285.5% | 0.04% | +221.4% |
| Q3 2022 | $234,000 | -52.1% | 7,634 | -49.8% | 0.01% | -56.2% |
| Q1 2022 | $489,000 | +48.6% | 15,203 | +106.3% | 0.03% | -22.0% |
| Q4 2021 | $329,000 | -11.6% | 7,369 | 0.0% | 0.04% | -18.0% |
| Q3 2021 | $372,000 | -31.1% | 7,369 | -76.2% | 0.05% | -68.9% |
| Q4 2019 | $540,000 | – | 30,974 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |